Journal of Diagnostics Concepts & Practice ›› 2024, Vol. 23 ›› Issue (05): 517-523.doi: 10.16150/j.1671-2870.2024.05.008

• Original articles • Previous Articles     Next Articles

Value of 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) in diagnosis of postoperative recurrence of pancreatic cancer

FENG Guowei, HUANG Xinyun, MENG Hongping, JIANG Xufeng, CHEN Kemin, LIN Xiaozhu()   

  1. Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; b. Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2024-06-08 Accepted:2024-10-08 Online:2024-10-25 Published:2025-02-25
  • Contact: LIN Xiaozhu E-mail:lxz11357@rjh.com.cn

Abstract:

Objective To evaluate the value of 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) in the diagnosis of postoperative recurrence of pancreatic cancer. Methods The study included 86 consecutive patients after resection of pancreatic cancer from April 2018 to December 2023, who underwent 18F-FDG PET/MRI from August to September 2024. The efficacy of 118F-FDG PET/MRI in detecting postoperative recurrence of pancreatic cancer was retrospectively analyzed, and compared with that of serum carbohydrate antigen 19-9 (CA19-9) concentration in the diagnosis of recurrence. Results Follow-up confirmed that 67.4% (58/86) of patients experienced recurrence. The primary tumor diameter in the recurrence group (3.4±1.3cm) was larger than in the non-recurrence group (2.7±1.2cm). Among the patients with recurrence, 87.9% (51/58) had systemic recurrence, with the most common sites being liver metastasis and peritoneal metastasis. PET/MRI results changed the treatment plans for 30.2% (26/86) of patients. Among the 86 cases, 79 patients underwent both PET/MRI and serum CA19-9 tests. PET/MRI showed higher diagnostic efficacy for detecting postoperative recurrence of pancreatic cancer compared to serum CA19-9 (AUC: 0.847 vs. 0.719 ). PET/MRI detected 9/12 cases of pancreatic cancer recurrence with normal serum CA19-9 levels, and excluded 5/8 patients with elevated serum CA19-9 levels who did not experience recurrence. Conclusions PET/MRI has great clinical value in the diagnosis of postoperative recurrence of pancreatic cancer. It is particularly meaningful for patients with normal serum CA19-9 level. It can not only diagnose recurrence but also provide the specific site of tumor recurrence and comprehensive information for the formulation of the next treatment plan.

Key words: Pancreatic ductal adenocarcinoma, Recurrence, 18F-FDG PET/MRI

CLC Number: